Database Query Results : Piperlongumine, ,

PL, Piperlongumine: Click to Expand ⟱
Features:
Piperlongumine (also called Piplartine), an alkaloid from long pepper fruit
-Piperlongumine is a bioactive alkaloid derived from the long pepper (Piper longum)
– Piperlongumine has been shown to selectively increase ROS levels in cancer cells.
-NLRP3 inhibitor?
-TrxR inhibitor (major antioxidant system) to increase ROS in cancer cells
-ic50 cancer cells maybe 2-10uM, normal cells maybe exceeding 20uM.

Available from mcsformulas.com
-(Long Pepper, 500mg/Capsule)- 1 capsule 3 times daily with food
-Piperlongumine Pro Liposomal, 40 mg-take 1 capsule daily with plenty of water, after a meal

-Note half-life 30–60 minutes
BioAv poor aqueous solubility and bioavailability
Pathways:
- induce ROS production in cancer cells likely at any dose. Effect on normal cells is inconclusive.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, Prx,
- Lowers some AntiOxidant markers/ defense in Cancer Cells: but mostly raises NRF2 (raises antiO defense), TrxR↓(*important), GSH↓ Catalase↓ HO1↓ GPx↓
- Very little indication of raising AntiOxidant defense in Normal Cells: GSH↑,
- lowers Inflammation : NF-kB↓, COX2↓, conversely p38↑, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMP2↓, MMP9↓, VEGF↓, NF-κB↓, CXCR4↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓(few reports), DNMT1↓, DNMT3A↓, EZH2↓, P53↑, HSP↓, Sp proteins↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, ERK↓, EMT↓,
- small indication of inhibiting glycolysis : HIF-1α↓, cMyc↓, LDH↓, HK2↓,
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, EGFR↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, β-catenin↓, ERK↓, JNK,
- Synergies: chemo-sensitization, RadioSensitizer, Others(review target notes), Neuroprotective, Cognitive, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells


Scientific Papers found: Click to Expand⟱
2964- PL,    Preformulation Studies on Piperlongumine
- Analysis, Nor, NA
"highlight2" >*BioAv↓, "highlight2" >*BioAv↑, "highlight2" >*other↝, "highlight2" >*eff↓,
2951- PL,  Aur,    Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells
- in-vitro, GBM, U87MG
"highlight2" >GSH↓, "highlight2" >eff↑, "highlight2" >GSTP1/GSTπ↓,
2952- PL,    Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization
- in-vitro, Bladder, T24 - in-vivo, Bladder, NA
"highlight2" >TumCP↓, "highlight2" >TumCCA↑, "highlight2" >TumCMig↓, "highlight2" >TumCI↓, "highlight2" >ROS↑, "highlight2" >Slug↓, "highlight2" >β-catenin/ZEB1↓, "highlight2" >Zeb1↓, "highlight2" >N-cadherin↓, "highlight2" >F-actin↓, "highlight2" >GSH↓, "highlight2" >EMT↓, "highlight2" >CLDN1↓, "highlight2" >ZO-1↓,
2953- PL,    Piperlongumine Acts as an Immunosuppressant by Exerting Prooxidative Effects in Human T Cells Resulting in Diminished TH17 but Enhanced Treg Differentiation
- in-vitro, Nor, NA
"highlight2" >*ROS↑, "highlight2" >*GSTA1↓, "highlight2" >eff↝, "highlight2" >*toxicity↓, "highlight2" >ROS↑, "highlight2" >*Hif1a↓,
2954- PL,    The metabolites from traditional Chinese medicine targeting ferroptosis for cancer therapy
- Review, Var, NA
"highlight2" >NRF2↑, "highlight2" >ROS↑, "highlight2" >ER Stress↑, "highlight2" >MAPK↑, "highlight2" >CHOP↑, "highlight2" >selectivity↑, "highlight2" >Keap1↝, "highlight2" >HO-1↑, "highlight2" >Ferroptosis↑,
2955- PL,    Heme Oxygenase-1 Determines the Differential Response of Breast Cancer and Normal Cells to Piperlongumine
- in-vitro, BC, MCF-7 - in-vitro, Nor, MCF10
"highlight2" >ROS?, "highlight2" >*ROS∅, "highlight2" >other⇅, "highlight2" >HO-1↑, "highlight2" >*HO-1↑, "highlight2" >NRF2↑, "highlight2" >Keap1↓, "highlight2" >cl‑PARP↑, "highlight2" >selectivity↑, "highlight2" >GSH↓, "highlight2" >GSSG↑,
2956- PL,    Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis
- in-vitro, PC, NA
"highlight2" >ROS↑, "highlight2" >Ferroptosis↓, "highlight2" >GSH↓, "highlight2" >GPx↓, "highlight2" >cl‑PARP∅, "highlight2" >cl‑Casp3∅, "highlight2" >eff↑, "highlight2" >eff↑,
2957- PL,    Piperlongumine Induces Cell Cycle Arrest via Reactive Oxygen Species Accumulation and IKKβ Suppression in Human Breast Cancer Cells
- in-vitro, BC, MCF-7
"highlight2" >TumCP↓, "highlight2" >TumCMig↓, "highlight2" >TumCCA↑, "highlight2" >ROS↑, "highlight2" >H2O2↑, "highlight2" >GSH↓, "highlight2" >IKKα↓, "highlight2" >NF-kB↓, "highlight2" >P21↑, "highlight2" >eff↓,
2958- PL,    Natural product piperlongumine inhibits proliferation of oral squamous carcinoma cells by inducing ferroptosis and inhibiting intracellular antioxidant capacity
- in-vitro, Oral, HSC3
"highlight2" >TumCP↓, "highlight2" >lipid-P↑, "highlight2" >ROS↑, "highlight2" >DNMT1↑, "highlight2" >FTH1↓, "highlight2" >GPx4↓, "highlight2" >eff↓, "highlight2" >GSH↓, "highlight2" >Ferroptosis↑, "highlight2" >MDA↓,
2959- PL,    Piperlongumine mitigates LPS-induced inflammation and lung injury via targeting MD2/TLR4
- in-vivo, Nor, NA
"highlight2" >*Inflam↓,
2960- PL,    Synthesis of Piperlongumine Analogues and Discovery of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators as Potential Neuroprotective Agents
- Analysis, Nor, NA
"highlight2" >NRF2↑, "highlight2" >neuroP↑,
2961- PL,    Piperlongumine inhibits esophageal squamous cell carcinoma in vitro and in vivo by triggering NRF2/ROS/TXNIP/NLRP3-dependent pyroptosis
- in-vitro, ESCC, KYSE-30
"highlight2" >Pyro↑, "highlight2" >TumCP↓, "highlight2" >TumCMig↓, "highlight2" >TumCI↓, "highlight2" >ASC↑, "highlight2" >cl‑Casp1↑, "highlight2" >NLRP3↑, "highlight2" >GSDMD↑, "highlight2" >ROS↑, "highlight2" >NRF2↓, "highlight2" >TXNIP↑,
2962- PL,    Synthesis of Piperlongumine Analogues and Discovery of Nuclear Factor Erythroid 2‑Related Factor 2 (Nrf2) Activators as Potential Neuroprotective Agents
- in-vitro, Nor, PC12
"highlight2" >*GSH↑, "highlight2" >*NQO1↑, "highlight2" >*Trx↑, "highlight2" >*TrxR↑, "highlight2" >*NRF2↑, "highlight2" >*NRF2⇅, "highlight2" >*eff↑, "highlight2" >*BioAv↑, "highlight2" >*ROS↓,
2963- PL,    Piperlongumine activates Sirtuin1 and improves cognitive function in a murine model of Alzheimer’s disease
- in-vitro, AD, HEK293
"highlight2" >*SIRT1↑, "highlight2" >*cognitive↑, "highlight2" >*Aβ↓, "highlight2" >*Inflam↓, "highlight2" >*neuroP↑, "highlight2" >memory↑, "highlight2" >Dose↓, "highlight2" >NAD↑,
2950- PL,    Overview of piperlongumine analogues and their therapeutic potential
- Review, Var, NA
"highlight2" >AntiAg↑, "highlight2" >neuroP↑, "highlight2" >Inflam↓, "highlight2" >NO↓, "highlight2" >PGE2↓, "highlight2" >MMP3↓, "highlight2" >MMP13↓, "highlight2" >TumCMig↓, "highlight2" >TumCI↓, "highlight2" >p38↑, "highlight2" >JNK↑, "highlight2" >NF-kB↑, "highlight2" >ROS↑, "highlight2" >Foxm1↓, "highlight2" >TrxR1↓, "highlight2" >GSH↓, "highlight2" >Trx↓, "highlight2" >cMyc↓, "highlight2" >Casp3↑, "highlight2" >Bcl-2↓, "highlight2" >Mcl-1↓, "highlight2" >STAT3↓, "highlight2" >AR↓, "highlight2" >DNAdam↑,
2965- PL,  docx,    Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in triple negative breast cancer
- Analysis, Var, NA
"highlight2" >BioEnh↑, "highlight2" >eff↑,
2966- PL,    A strategy to improve the solubility and bioavailability of the insoluble drug piperlongumine through albumin nanoparticles
- in-vitro, LiverDam, NA
"highlight2" >*Half-Life↑, "highlight2" >*BioAv↑, "highlight2" >eff↑, "highlight2" >ROS↑,
2967- PL,    Piperlongumine and its derivatives against cancer: A recent update and future prospective
- Review, Var, NA
"highlight2" >BioAv↓, "highlight2" >BioAv↑,
2968- PL,  Chit,    Preparation of piperlongumine-loaded chitosan nanoparticles for safe and efficient cancer therapy
- in-vitro, GC, AGS
"highlight2" >eff↑, "highlight2" >Dose↝, "highlight2" >ROS↑, "highlight2" >BioAv↑,
2969- PL,    Piperlongumine induces autophagy by targeting p38 signaling
- in-vitro, OS, U2OS - in-vitro, Cerv, HeLa
"highlight2" >p38↑, "highlight2" >ROS↑, "highlight2" >GPx1∅, "highlight2" >SOD∅, "highlight2" >Catalase∅,
2970- PL,    Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways
- in-vitro, AML, NA
"highlight2" >AntiAg↑, "highlight2" >TumCG↓, "highlight2" >Apoptosis↑, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >mTOR↓, "highlight2" >p38↑, "highlight2" >Casp3↑,
2971- PL,    Piperlongumine attenuates IL-1β-induced inflammatory response in chondrocytes
- NA, OS, NA
"highlight2" >*NO↓, "highlight2" >*PGE2↓, "highlight2" >*iNOS↓, "highlight2" >*COX2↓, "highlight2" >*MMP3↑, "highlight2" >*MMP13↓, "highlight2" >*Inflam↓,
2972- PL,    Piperlongumine Is an NLRP3 Inhibitor With Anti-inflammatory Activity
- in-vitro, AML, THP1
"highlight2" >NLRP3↓, "highlight2" >IL1β↓, "highlight2" >LDH↓, "highlight2" >cl‑Casp1↓, "highlight2" >Inflam↓,
2973- PL,    The Natural Alkaloid Piperlongumine Inhibits Metastatic Activity and Epithelial-to-Mesenchymal Transition of Triple-Negative Mammary Carcinoma Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, 4T1
"highlight2" >MMP2↓, "highlight2" >MMP9↓, "highlight2" >IL6↓, "highlight2" >E-cadherin↑, "highlight2" >ROS↑, "highlight2" >EMT↓, "highlight2" >Zeb1↓, "highlight2" >Slug↓, "highlight2" >TumMeta↓, "highlight2" >selectivity↑, "highlight2" >NA↑, "highlight2" >GSH↓,
2995- PL,    Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover
- in-vitro, Lung, H1975 - in-vitro, Lung, PC9 - in-vivo, NA, NA
"highlight2" >Sp1/3/4↓, "highlight2" >cMET↓, "highlight2" >Apoptosis↑, "highlight2" >Cyt‑c↑, "highlight2" >p‑ERK↓, "highlight2" >p‑Akt↓, "highlight2" >TumCG↓,
2996- PL,    Application of longinamide in inhibiting the activation of NLRP3 inflammasome
- NA, AD, NA - NA, Park, NA
"highlight2" >*NLRP3↓,
2999- PL,    Piperlongumine alleviates corneal allograft rejection via suppressing angiogenesis and inflammation
- in-vivo, Nor, HUVECs
"highlight2" >*Inflam↓, "highlight2" >*angioG↓, "highlight2" >*Hif1a↓, "highlight2" >*VEGF↓, "highlight2" >*ICAM-1↓, "highlight2" >*VCAM-1↓, "highlight2" >*neuroP↑,
3000- PL,    Biological and physical approaches on the role of piplartine (piperlongumine) in cancer
- in-vitro, Nor, HUVECs - in-vitro, Laryn, HEp2
"highlight2" >Inflam↓, "highlight2" >AntiTum↑, "highlight2" >*α-tubulin↓, "highlight2" >selectivity↑, "highlight2" >HIF2a↓, "highlight2" >MCP1↓,
1951- PL,    Piperlongumine Analogs Promote A549 Cell Apoptosis through Enhancing ROS Generation
- in-vitro, Lung, A549
"highlight2" >ROS↑, "highlight2" >lipid-P↑, "highlight2" >MMP↓, "highlight2" >TumCCA↑, "highlight2" >TrxR↓, "highlight2" >eff↑,
1938- PL,    Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation
- Study, PSA, NA - in-vivo, NA, NA
"highlight2" >ROS↑, "highlight2" >Apoptosis↑, "highlight2" >MMP↓, "highlight2" >TumCCA↑, "highlight2" >DNAdam↑, "highlight2" >STAT3↓, "highlight2" >Akt↓, "highlight2" >PCNA↓, "highlight2" >Ki-67↓, "highlight2" >cycD1↓, "highlight2" >Bcl-2↓, "highlight2" >K17↓, "highlight2" >HDAC↓, "highlight2" >ROS↑, "highlight2" >*IL1β↓, "highlight2" >*IL6↓, "highlight2" >*TNF-α↓, "highlight2" >*IL17↓, "highlight2" >*IL22↓,
1939- PL,    Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP
- in-vitro, HCC, HepG2 - in-vitro, HCC, HUH7 - in-vivo, NA, NA
"highlight2" >TumCMig↓, "highlight2" >TumCI↓, "highlight2" >ER Stress↑, "highlight2" >selectivity↑, "highlight2" >tumCV↓, "highlight2" >ROS↑, "highlight2" >GSH↓, "highlight2" >eff↓, "highlight2" >Ca+2↑, "highlight2" >MAPK↑, "highlight2" >CHOP↑, "highlight2" >Dose↝,
1940- PL,    Piperlongumine Inhibits Migration of Glioblastoma Cells via Activation of ROS-Dependent p38 and JNK Signaling Pathways
- in-vitro, GBM, LN229 - in-vitro, GBM, U87MG
"highlight2" >ROS↑, "highlight2" >GSH↓, "highlight2" >p38↑, "highlight2" >JNK↑, "highlight2" >IKKα↑, "highlight2" >NF-kB↓, "highlight2" >eff↓,
1941- PL,    Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer
- in-vitro, HNSCC, NA
"highlight2" >selectivity↑, "highlight2" >eff↑, "highlight2" >ROS↑, "highlight2" >toxicity↑, "highlight2" >GSH↓, "highlight2" >GSSG↑, "highlight2" >*GSSG∅, "highlight2" >cl‑PARP↑, "highlight2" >PUMA↑, "highlight2" >GSTP1/GSTπ↓, "highlight2" >ChemoSen↑,
1942- PL,    Piperlongumine inhibits antioxidant enzymes, increases ROS levels, induces DNA damage and G2/M cell cycle arrest in breast cell lines
- in-vitro, BC, MCF-7
"highlight2" >ROS↑, "highlight2" >SOD1↑, "highlight2" >Trx1↓, "highlight2" >Catalase↓, "highlight2" >PrxII↓, "highlight2" >ROS↑, "highlight2" >GADD45A↑, "highlight2" >P21↑, "highlight2" >DNAdam↑, "highlight2" >TumCCA↑,
1943- PL,    Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells
- in-vitro, GBM, NA - in-vivo, NA, NA
"highlight2" >selectivity↑, "highlight2" >ROS↑, "highlight2" >selectivity↑, "highlight2" >Prx4↓, "highlight2" >*Prx4∅, "highlight2" >ER Stress↑, "highlight2" >CHOP↑, "highlight2" >UPR↑,
1944- PL,    Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress
- in-vitro, HCC, HUH7 - in-vitro, HCC, HepG2
"highlight2" >ER Stress↑, "highlight2" >TrxR1↓, "highlight2" >ROS↑, "highlight2" >eff↓, "highlight2" >Bcl-2↓, "highlight2" >proCasp3↓, "highlight2" >BAX↓, "highlight2" >cl‑Casp3↑, "highlight2" >TumCCA↑, "highlight2" >p‑PERK↑, "highlight2" >ATF4↑, "highlight2" >TumCG↓, "highlight2" >lipid-P↑, "highlight2" >selectivity↑,
1945- PL,  SANG,    The Synergistic Effect of Piperlongumine and Sanguinarine on the Non-Small Lung Cancer
- in-vitro, Lung, A549
"highlight2" >toxicity∅, "highlight2" >Apoptosis↑, "highlight2" >TumMeta↓, "highlight2" >ROS↑, "highlight2" >TumCCA↑,
1946- PL,  PI,    Piperlonguminine and Piperine Analogues as TrxR Inhibitors that Promote ROS and Autophagy and Regulate p38 and Akt/mTOR Signaling
- in-vitro, Liver, NA
"highlight2" >eff↑, "highlight2" >toxicity↓, "highlight2" >TrxR↓, "highlight2" >ROS↑, "highlight2" >MMP↓, "highlight2" >p38↑, "highlight2" >Akt↓, "highlight2" >mTOR↓,
1947- PL,    Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer
- in-vitro, GC, SGC-7901 - in-vitro, GC, NA
"highlight2" >TrxR1↓, "highlight2" >ROS↑, "highlight2" >ER Stress↑, "highlight2" >mtDam↑, "highlight2" >selectivity↑, "highlight2" >NO↑, "highlight2" >TumCCA↑, "highlight2" >mt-ROS↑, "highlight2" >Casp9↑, "highlight2" >Bcl-2↓, "highlight2" >Bcl-xL↓, "highlight2" >cl‑PARP↑, "highlight2" >eff↓, "highlight2" >lipid-P↑,
1948- PL,  born,    Natural borneol serves as an adjuvant agent to promote the cellular uptake of piperlongumine for improving its antiglioma efficacy
- in-vitro, GBM, NA
"highlight2" >selectivity↑, "highlight2" >ROS↑, "highlight2" >BioAv↓, "highlight2" >BioAv↑, "highlight2" >Apoptosis↑, "highlight2" >TumCCA↑, "highlight2" >eff↑,
1949- PL,    Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor
- in-vitro, CRC, HCT116 - in-vitro, Cerv, HeLa
"highlight2" >TrxR↓, "highlight2" >selectivity↑, "highlight2" >ROS↑, "highlight2" >IDO1↓,
1950- PL,    Increased Expression of FosB through Reactive Oxygen Species Accumulation Functions as Pro-Apoptotic Protein in Piperlongumine Treated MCF7 Breast Cancer Cells
- in-vitro, BC, MCF-7 - in-vitro, Lung, A549
"highlight2" >selectivity↑, "highlight2" >ROS↑, "highlight2" >SETBP1↓, "highlight2" >cl‑Casp9↑, "highlight2" >eff↓, "highlight2" >FOSB↑,
992- PL,    Piperlongumine based nanomedicine impairs glycolytic metabolism in triple negative breast cancer stem cells through modulation of GAPDH & FBP1
- in-vivo, BC, NA
"highlight2" >EPR↓, "highlight2" >Glycolysis↓, "highlight2" >GAPDH↓, "highlight2" >GSTP1/GSTπ↝, "highlight2" >FBPase↑,
1952- PL,  5-FU,    Piperlongumine induces ROS accumulation to reverse resistance of 5-FU in human colorectal cancer via targeting TrxR
- in-vivo, CRC, HCT8
"highlight2" >ROS↑, "highlight2" >TrxR↓, "highlight2" >eff↑, "highlight2" >p‑Akt↓,
1953- PL,    Designing piperlongumine-directed anticancer agents by an electrophilicity-based prooxidant strategy: A mechanistic investigation
- in-vitro, Lung, A549 - in-vitro, Nor, WI38
"highlight2" >ROS↑, "highlight2" >selectivity↑, "highlight2" >TrxR↓, "highlight2" >TumCCA↑, "highlight2" >GSH?, "highlight2" >H2O2↑,
2649- PL,    Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence
- Review, Var, NA
"highlight2" >AntiCan↑, "highlight2" >ROS↑, "highlight2" >GSH↓, "highlight2" >TrxR↓, "highlight2" >Trx↓, "highlight2" >Apoptosis↑, "highlight2" >TumCCA↑, "highlight2" >ER Stress↑, "highlight2" >DNAdam↑, "highlight2" >ChemoSen↑, "highlight2" >BioAv↓,
2940- PL,    Piperlongumine Induces Reactive Oxygen Species (ROS)-dependent Downregulation of Specificity Protein Transcription Factors
- in-vitro, PC, PANC1 - in-vitro, Lung, A549 - in-vitro, Kidney, 786-O - in-vitro, BC, SkBr3
"highlight2" >ROS↑, "highlight2" >TumCP↓, "highlight2" >Apoptosis↑, "highlight2" >eff↓, "highlight2" >Sp1/3/4↓, "highlight2" >cycD1↓, "highlight2" >survivin↓, "highlight2" >cMyc↓, "highlight2" >EGFR↓, "highlight2" >cMET↓,
2941- PL,    Selective killing of cancer cells by a small molecule targeting the stress response to ROS
- in-vivo, BC, MDA-MB-231 - in-vitro, OS, U2OS - in-vitro, BC, MDA-MB-453
"highlight2" >ROS↑, "highlight2" >Apoptosis↑, "highlight2" >selectivity↑, "highlight2" >*ROS∅, "highlight2" >GSH↓, "highlight2" >GSSG↑, "highlight2" >H2O2↑, "highlight2" >NO↑, "highlight2" >Half-Life?,
2942- PL,    Piperlongumine increases sensitivity of colorectal cancer cells to radiation: Involvement of ROS production via dual inhibition of glutathione and thioredoxin systems
- in-vitro, CRC, CT26 - in-vitro, CRC, DLD1 - in-vivo, CRC, CT26
"highlight2" >ROS↑, "highlight2" >GSH↓, "highlight2" >TrxR↓, "highlight2" >RadioS↑, "highlight2" >DNAdam↑, "highlight2" >TumCCA↑, "highlight2" >mitResp↓, "highlight2" >GSTs↓, "highlight2" >OS↑,
2943- PL,    Piperlongumine Inhibits Thioredoxin Reductase 1 by Targeting Selenocysteine Residues and Sensitizes Cancer Cells to Erastin
- in-vitro, CRC, HCT116 - in-vitro, Lung, A549 - in-vitro, BC, MCF-7
"highlight2" >TrxR1?, "highlight2" >TumCD↑, "highlight2" >ROS↑, "highlight2" >GSH↓, "highlight2" >eff↑,
2944- PL,    Piperlongumine, a Potent Anticancer Phytotherapeutic, Induces Cell Cycle Arrest and Apoptosis In Vitro and In Vivo through the ROS/Akt Pathway in Human Thyroid Cancer Cells
- in-vitro, Thyroid, IHH4 - in-vitro, Thyroid, 8505C - in-vivo, NA, NA
"highlight2" >ROS↑, "highlight2" >selectivity↑, "highlight2" >tumCV↓, "highlight2" >TumCCA↑, "highlight2" >Apoptosis↑, "highlight2" >ERK↑, "highlight2" >Akt↓, "highlight2" >mTOR↓, "highlight2" >neuroP↑, "highlight2" >Bcl-2↓, "highlight2" >Casp3↑, "highlight2" >PARP↑, "highlight2" >JNK↑, "highlight2" >*toxicity↓, "highlight2" >eff↓, "highlight2" >TumW↓,
2945- PL,    Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells
- in-vitro, CRC, HCT116
"highlight2" >ROS↑, "highlight2" >SMAD4↑, "highlight2" >ChemoSen↑, "highlight2" >P53↑, "highlight2" >P21↑, "highlight2" >BAX↑, "highlight2" >Bcl-2↓, "highlight2" >survivin↓, "highlight2" >TumCMig↓,
2946- PL,    Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- Review, Var, NA
"highlight2" >ROS↑, "highlight2" >GSH↓, "highlight2" >DNAdam↑, "highlight2" >ChemoSen↑, "highlight2" >RadioS↑, "highlight2" >BioEnh↑, "highlight2" >selectivity↑, "highlight2" >BioAv↓, "highlight2" >eff↑, "highlight2" >p‑Akt↓, "highlight2" >mTOR↓, "highlight2" >GSK‐3β↓, "highlight2" >β-catenin/ZEB1↓, "highlight2" >HK2↓, "highlight2" >Glycolysis↓, "highlight2" >Cyt‑c↑, "highlight2" >Casp9↑, "highlight2" >Casp3↑, "highlight2" >Casp7↑, "highlight2" >cl‑PARP↑, "highlight2" >TrxR↓, "highlight2" >ER Stress↑, "highlight2" >ATF4↝, "highlight2" >CHOP↑, "highlight2" >Prx4↑, "highlight2" >NF-kB↓, "highlight2" >cycD1↓, "highlight2" >CDK4↓, "highlight2" >CDK6↓, "highlight2" >p‑RB1↓, "highlight2" >RAS↓, "highlight2" >cMyc↓, "highlight2" >TumCCA↑, "highlight2" >selectivity↑, "highlight2" >STAT3↓, "highlight2" >NRF2↑, "highlight2" >HO-1↑, "highlight2" >PTEN↑, "highlight2" >P-gp↓, "highlight2" >MDR1↓, "highlight2" >MRP1↓, "highlight2" >survivin↓, "highlight2" >Twist↓, "highlight2" >AP-1↓, "highlight2" >Sp1/3/4↓, "highlight2" >STAT1↓, "highlight2" >STAT6↓, "highlight2" >SOX4↑, "highlight2" >XBP-1↑, "highlight2" >P21↑, "highlight2" >eff↑, "highlight2" >Inflam↓, "highlight2" >COX2↓, "highlight2" >IL6↓, "highlight2" >MMP9↓, "highlight2" >TumMeta↓, "highlight2" >TumCI↓, "highlight2" >ICAM-1↓, "highlight2" >CXCR4↓, "highlight2" >VEGF↓, "highlight2" >angioG↓, "highlight2" >Half-Life↝, "highlight2" >BioAv↑,
2947- PL,    Piperlongumine: the amazing amide alkaloid from Piper in the treatment of breast cancer
- Review, Var, NA
"highlight2" >TumCP↓, "highlight2" >Apoptosis↑, "highlight2" >TumCCA↑, "highlight2" >ROS↑,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
"highlight2" >tumCV↓, "highlight2" >TumCP↓, "highlight2" >TumCI↓, "highlight2" >angioG↓, "highlight2" >EMT↓, "highlight2" >TumMeta↓, "highlight2" >*hepatoP↑, "highlight2" >*lipid-P↓, "highlight2" >*GSH↑, "highlight2" >cardioP↑, "highlight2" >CycB↓, "highlight2" >cycD1↓, "highlight2" >CDK2↓, "highlight2" >CDK1↓, "highlight2" >CDK4↓, "highlight2" >CDK6↓, "highlight2" >PCNA↓, "highlight2" >Akt↓, "highlight2" >mTOR↓, "highlight2" >Glycolysis↓, "highlight2" >NF-kB↓, "highlight2" >IKKα↓, "highlight2" >JAK1↓, "highlight2" >JAK2↓, "highlight2" >STAT3↓, "highlight2" >ERK↓, "highlight2" >cFos↓, "highlight2" >Slug↓, "highlight2" >E-cadherin↑, "highlight2" >TOP2↓, "highlight2" >P53↑, "highlight2" >P21↑, "highlight2" >Bcl-2↓, "highlight2" >BAX↑, "highlight2" >Casp3↑, "highlight2" >Casp7↑, "highlight2" >Casp8↑, "highlight2" >p‑HER2/EBBR2↓, "highlight2" >HO-1↑, "highlight2" >NRF2↑, "highlight2" >BIM↑, "highlight2" >p‑FOXO3↓, "highlight2" >NA↓, "highlight2" >Sp1/3/4↓, "highlight2" >cMyc↓, "highlight2" >EGFR↓, "highlight2" >survivin↓, "highlight2" >cMET↓, "highlight2" >NQO1↑, "highlight2" >SOD2↑, "highlight2" >TrxR↓, "highlight2" >MDM2↓, "highlight2" >p‑eIF2α↑, "highlight2" >ATF4↑, "highlight2" >CHOP↑, "highlight2" >MDA↑, "highlight2" >Ki-67↓, "highlight2" >MMP9↓, "highlight2" >Twist↓, "highlight2" >SOX2↓, "highlight2" >Nanog↓, "highlight2" >OCT4↓, "highlight2" >N-cadherin↓, "highlight2" >Vim↓, "highlight2" >Snail↓, "highlight2" >TumW↓, "highlight2" >TumCG↓, "highlight2" >HK2↓, "highlight2" >RB1↓, "highlight2" >IL6↓, "highlight2" >IL8↓, "highlight2" >SOD1↑, "highlight2" >RadioS↑, "highlight2" >ChemoSen↑, "highlight2" >toxicity↓, "highlight2" >Sp1/3/4↓, "highlight2" >GSH↓, "highlight2" >SOD↑,
2949- PL,    Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation
- in-vitro, GBM, LN229 - in-vitro, GBM, U87MG
"highlight2" >selectivity↑, "highlight2" >ROS↑, "highlight2" >JNK↑, "highlight2" >p38↑, "highlight2" >GSH↓, "highlight2" >eff↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 56

Results for Effect on Cancer/Diseased Cells:
Akt↓,5,   p‑Akt↓,3,   angioG↓,2,   AntiAg↑,2,   AntiCan↑,1,   AntiTum↑,1,   AP-1↓,1,   Apoptosis↑,10,   AR↓,1,   ASC↑,1,   ATF4↑,2,   ATF4↝,1,   BAX↓,1,   BAX↑,2,   Bcl-2↓,7,   Bcl-xL↓,1,   BIM↑,1,   BioAv↓,4,   BioAv↑,4,   BioEnh↑,2,   Ca+2↑,1,   cardioP↑,1,   cl‑Casp1↓,1,   cl‑Casp1↑,1,   Casp3↑,5,   cl‑Casp3↑,1,   cl‑Casp3∅,1,   proCasp3↓,1,   Casp7↑,2,   Casp8↑,1,   Casp9↑,2,   cl‑Casp9↑,1,   Catalase↓,1,   Catalase∅,1,   CDK1↓,1,   CDK2↓,1,   CDK4↓,2,   CDK6↓,2,   cFos↓,1,   ChemoSen↑,5,   CHOP↑,5,   CLDN1↓,1,   cMET↓,3,   cMyc↓,4,   COX2↓,1,   CXCR4↓,1,   CycB↓,1,   cycD1↓,4,   Cyt‑c↑,2,   DNAdam↑,6,   DNMT1↑,1,   Dose↓,1,   Dose↝,2,   E-cadherin↑,2,   eff↓,10,   eff↑,14,   eff↝,1,   EGFR↓,2,   p‑eIF2α↑,1,   EMT↓,3,   EPR↓,1,   ER Stress↑,7,   ERK↓,1,   ERK↑,1,   p‑ERK↓,1,   F-actin↓,1,   FBPase↑,1,   Ferroptosis↓,1,   Ferroptosis↑,2,   FOSB↑,1,   Foxm1↓,1,   p‑FOXO3↓,1,   FTH1↓,1,   GADD45A↑,1,   GAPDH↓,1,   Glycolysis↓,3,   GPx↓,1,   GPx1∅,1,   GPx4↓,1,   GSDMD↑,1,   GSH?,1,   GSH↓,18,   GSK‐3β↓,1,   GSSG↑,3,   GSTP1/GSTπ↓,2,   GSTP1/GSTπ↝,1,   GSTs↓,1,   H2O2↑,3,   Half-Life?,1,   Half-Life↝,1,   HDAC↓,1,   p‑HER2/EBBR2↓,1,   HIF2a↓,1,   HK2↓,2,   HO-1↑,4,   ICAM-1↓,1,   IDO1↓,1,   IKKα↓,2,   IKKα↑,1,   IL1β↓,1,   IL6↓,3,   IL8↓,1,   Inflam↓,4,   JAK1↓,1,   JAK2↓,1,   JNK↑,4,   K17↓,1,   Keap1↓,1,   Keap1↝,1,   Ki-67↓,2,   LDH↓,1,   lipid-P↑,4,   MAPK↑,2,   Mcl-1↓,1,   MCP1↓,1,   MDA↓,1,   MDA↑,1,   MDM2↓,1,   MDR1↓,1,   memory↑,1,   mitResp↓,1,   MMP↓,3,   MMP13↓,1,   MMP2↓,1,   MMP3↓,1,   MMP9↓,3,   MRP1↓,1,   mtDam↑,1,   mTOR↓,5,   N-cadherin↓,2,   NA↓,1,   NA↑,1,   NAD↑,1,   Nanog↓,1,   neuroP↑,3,   NF-kB↓,4,   NF-kB↑,1,   NLRP3↓,1,   NLRP3↑,1,   NO↓,1,   NO↑,2,   NQO1↑,1,   NRF2↓,1,   NRF2↑,5,   OCT4↓,1,   OS↑,1,   other⇅,1,   P-gp↓,1,   P21↑,5,   p38↑,6,   P53↑,2,   PARP↑,1,   cl‑PARP↑,4,   cl‑PARP∅,1,   PCNA↓,2,   p‑PERK↑,1,   PGE2↓,1,   PI3K↓,1,   Prx4↓,1,   Prx4↑,1,   PrxII↓,1,   PTEN↑,1,   PUMA↑,1,   Pyro↑,1,   RadioS↑,3,   RAS↓,1,   RB1↓,1,   p‑RB1↓,1,   ROS?,1,   ROS↑,40,   mt-ROS↑,1,   selectivity↑,19,   SETBP1↓,1,   Slug↓,3,   SMAD4↑,1,   Snail↓,1,   SOD↑,1,   SOD∅,1,   SOD1↑,2,   SOD2↑,1,   SOX2↓,1,   SOX4↑,1,   Sp1/3/4↓,5,   STAT1↓,1,   STAT3↓,4,   STAT6↓,1,   survivin↓,4,   TOP2↓,1,   toxicity↓,2,   toxicity↑,1,   toxicity∅,1,   Trx↓,2,   Trx1↓,1,   TrxR↓,9,   TrxR1?,1,   TrxR1↓,3,   TumCCA↑,15,   TumCD↑,1,   TumCG↓,4,   TumCI↓,6,   TumCMig↓,6,   TumCP↓,7,   tumCV↓,3,   TumMeta↓,4,   TumW↓,2,   Twist↓,2,   TXNIP↑,1,   UPR↑,1,   VEGF↓,1,   Vim↓,1,   XBP-1↑,1,   Zeb1↓,2,   ZO-1↓,1,   β-catenin/ZEB1↓,2,  
Total Targets: 214

Results for Effect on Normal Cells:
angioG↓,1,   Aβ↓,1,   BioAv↓,1,   BioAv↑,3,   cognitive↑,1,   COX2↓,1,   eff↓,1,   eff↑,1,   GSH↑,2,   GSSG∅,1,   GSTA1↓,1,   Half-Life↑,1,   hepatoP↑,1,   Hif1a↓,2,   HO-1↑,1,   ICAM-1↓,1,   IL17↓,1,   IL1β↓,1,   IL22↓,1,   IL6↓,1,   Inflam↓,4,   iNOS↓,1,   lipid-P↓,1,   MMP13↓,1,   MMP3↑,1,   neuroP↑,2,   NLRP3↓,1,   NO↓,1,   NQO1↑,1,   NRF2↑,1,   NRF2⇅,1,   other↝,1,   PGE2↓,1,   Prx4∅,1,   ROS↓,1,   ROS↑,1,   ROS∅,2,   SIRT1↑,1,   TNF-α↓,1,   toxicity↓,2,   Trx↑,1,   TrxR↑,1,   VCAM-1↓,1,   VEGF↓,1,   α-tubulin↓,1,  
Total Targets: 45

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:134  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page